Anti-Obesity Drug Interventions and Novel Drug Development

Engineering Next-Generation Multispecifics: Discovery of AMG 133 as a First-in-Class GIPR Antagonist and GLP-1R Agonist Conjugate for Obesity

September 16, 2026

Beyond the Scale: Redefining Success in Modern Evidence-Based Obesity Care

June 22, 2026

Targeting ActRII and GLP-1 Receptor Agonists: A New Era of High-Quality Weight Loss with Muscle Preservation

June 22, 2026

Unlocking the Anti-Obesity Potential of 6,7-Dihydroxy-4-methylcoumarin: Insights into Adipogenesis Inhibition

November 7, 2025